Evidence map›Paper›PMID 32192047›Full record

ReviewCancers2020

MicroRNAs in Cancer Treatment-Induced Cardiotoxicity.

Laura Pellegrini, Sara Sileno, Marco D'Agostino, Eleonora Foglio, Maria Cristina Florio, Vincenzo Guzzanti, Matteo Antonio Russo, Federica Limana, Alessandra Magenta

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 1 synthesis or guideline pooled it, 38 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 3 countries.

Laura PellegriniInstitute of Oncology Research (IOR), 6500 Bellinzona, Switzerland.
Sara SilenoIstituto Dermopatico dell'Immacolata, IDI-IRCCS, Experimental Immunology Laboratory, Via dei Monti di Creta 104, 00167 Rome, Italy.
Marco D'AgostinoIstituto Dermopatico dell'Immacolata, IDI-IRCCS, Experimental Immunology Laboratory, Via dei Monti di Creta 104, 00167 Rome, Italy.
Eleonora FoglioDepartment of Experimental Medicine, Sapienza University of Rome, 00161 Rome, Italy.
Maria Cristina FlorioLaboratory of Cardiovascular Science, National Institute on Aging, National Institutes of Health, Baltimore, MD 21224, USA.
Vincenzo GuzzantiIstituto Dermopatico dell'Immacolata, IDI-IRCCS, 00167 Rome, Italy.
Matteo Antonio RussoIRCCS San Raffaele Pisana and MEBIC Consortium, 00166 Rome, Italy.
Federica LimanaSan Raffaele Open University, 00166 Rome, Italy.
Alessandra MagentaIstituto Dermopatico dell'Immacolata, IDI-IRCCS, Experimental Immunology Laboratory, Via dei Monti di Creta 104, 00167 Rome, Italy.ORCID 0000-0002-9054-337X
Istituto Dermopatico dell'Immacolata · ITSan Raffaele University of Rome · ITInstitute of Oncology Research · CHNational Institutes of Health · USSapienza University of Rome · IT

Funding

AFM-Téléthon 22522Ministero della Salute RF-02362708Ministero della Salute SG-12358253NIH HHS Intramural Research
6 · The paper itself

Abstract

Cancer treatment has made significant progress in the cure of different types of tumors. Nevertheless, its clinical use is limited by unwanted cardiotoxicity. Aside from the conventional chemotherapy approaches, even the most newly developed, i.e., molecularly targeted therapy and immunotherapy, exhibit a similar frequency and severity of toxicities that range from subclinical ventricular dysfunction to severe cardiomyopathy and, ultimately, congestive heart failure. Specific mechanisms leading to cardiotoxicity still remain to be elucidated. For instance, oxidative stress and DNA damage are considered key players in mediating cardiotoxicity in different treatments. microRNAs (miRNAs) act as key regulators in cell proliferation, cell death, apoptosis, and cell differentiation. Their dysregulation has been associated with adverse cardiac remodeling and toxicity. This review provides an overview of the cardiotoxicity induced by different oncologic treatments and potential miRNAs involved in this effect that could be used as possible therapeutic targets.

Indexed as

cancer therapycardiotoxicitycardiovascular diseasesmicroRNAs

Identifiers

PMID32192047
PMCPMC7140035
OpenAlexW3011089525

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.